Correlation Between Invivyd and Aligos Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Invivyd and Aligos Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Invivyd and Aligos Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Invivyd and Aligos Therapeutics, you can compare the effects of market volatilities on Invivyd and Aligos Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Invivyd with a short position of Aligos Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Invivyd and Aligos Therapeutics.

Diversification Opportunities for Invivyd and Aligos Therapeutics

-0.61
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Invivyd and Aligos is -0.61. Overlapping area represents the amount of risk that can be diversified away by holding Invivyd and Aligos Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aligos Therapeutics and Invivyd is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Invivyd are associated (or correlated) with Aligos Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aligos Therapeutics has no effect on the direction of Invivyd i.e., Invivyd and Aligos Therapeutics go up and down completely randomly.

Pair Corralation between Invivyd and Aligos Therapeutics

Given the investment horizon of 90 days Invivyd is expected to under-perform the Aligos Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Invivyd is 1.53 times less risky than Aligos Therapeutics. The stock trades about -0.15 of its potential returns per unit of risk. The Aligos Therapeutics is currently generating about 0.51 of returns per unit of risk over similar time horizon. If you would invest  955.00  in Aligos Therapeutics on September 2, 2024 and sell it today you would earn a total of  1,596  from holding Aligos Therapeutics or generate 167.12% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Invivyd  vs.  Aligos Therapeutics

 Performance 
       Timeline  
Invivyd 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Invivyd has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Invivyd is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.
Aligos Therapeutics 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Aligos Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak technical and fundamental indicators, Aligos Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Invivyd and Aligos Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Invivyd and Aligos Therapeutics

The main advantage of trading using opposite Invivyd and Aligos Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Invivyd position performs unexpectedly, Aligos Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aligos Therapeutics will offset losses from the drop in Aligos Therapeutics' long position.
The idea behind Invivyd and Aligos Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Other Complementary Tools

Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals